Compound News and Research

RSS

Jagaricin and antifungal drugs: an interview with Prof Christian Hertweck

Most people have already experienced a fungal infection (mycosis) of the outer layer of the skin, athlete’s foot or ringworm. Whereas such infections may be cumbersome and often difficult to cure, usually they are not dangerous. However, in cases where a fungus causes a systemic infection, this is, it infects internal organs such as lungs or brain, the infection may turn into a life-threatening disease. Of course, only pathogenic fungi cause problems and the degree of virulence varies.

18 Dec 2012

PRSS3 enzyme linked to aggressive prostate cancer

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.

18 Dec 2012

UCSD Moores Cancer Center offers insights into flavorful healthy foods

What's round, red, full of holiday cheer, and (dare we say it) good for you? It's the cranberry. Its powerful goodness, coupled with cruciferous vegetables- such as broccoli, bok choy, and kale- and festive seasonal fruits like persimmons, can change attitudes about "healthy" eating during the holidays. Gain some flavorful food insights in Food for Thought: Healing Foods to Savor, authored by nutritional experts at University of California, San Diego Moores Cancer Center.

18 Dec 2012

Experts warn banning thimerosal from use in vaccines would harm immunization campaigns in developing world

"A group of prominent doctors and public health experts warns in articles to be published Monday in the journal Pediatrics that banning thimerosal, a mercury compound used as a preservative in vaccines, would devastate public health efforts in developing countries," the New York Times reports.

17 Dec 2012

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration for the development of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).

17 Dec 2012

Naurex announces completion of $38M Series B financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of a $38 million Series B financing led by new investor Baxter Ventures.

17 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

Paroxetine could treat vascular complications of diabetes

University of Texas Medical Branch at Galveston researchers have discovered that the commonly used antidepressant drug paroxetine could also become a therapy for the vascular complications of diabetes.

14 Dec 2012

Rural residents of Utah less likely to follow colorectal cancer screening recommendations

People who reside in rural areas of Utah are less likely to follow colorectal cancer (CRC) screening recommendations than their urban counterparts, according to researchers from Huntsman Cancer Institute (HCI) at the University of Utah.

13 Dec 2012

New way to effectively make designer drugs that hit collections of protein targets simultaneously

An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

13 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Potential way to attack common stomach bacteria that cause ulcers

Experiments at the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory have revealed a potential new way to attack common stomach bacteria that cause ulcers and significantly increase the odds of developing stomach cancer.

10 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

Scientists identify novel mechanism by which ketogenic diet could delay effects of aging

Scientists at the Gladstone Institutes have identified a novel mechanism by which a type of low-carb, low-calorie diet-called a "ketogenic diet"-could delay the effects of aging. This fundamental discovery reveals how such a diet could slow the aging process and may one day allow scientists to better treat or prevent age-related diseases, including heart disease, Alzheimer's disease and many forms of cancer.

6 Dec 2012

Compound News and Research

Jagaricin and antifungal drugs: an interview with Prof Christian Hertweck

PRSS3 enzyme linked to aggressive prostate cancer

UCSD Moores Cancer Center offers insights into flavorful healthy foods

Experts warn banning thimerosal from use in vaccines would harm immunization campaigns in developing world

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Naurex announces completion of $38M Series B financing

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Paroxetine could treat vascular complications of diabetes

Rural residents of Utah less likely to follow colorectal cancer screening recommendations

New way to effectively make designer drugs that hit collections of protein targets simultaneously

Weill Cornell research team develops new experimental drug therapy to target DLBCL

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Potential way to attack common stomach bacteria that cause ulcers

New study could help develop anti-inflammatory drugs with fewer side effects

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Ibrutinib may effectively combat chronic lymphocytic leukemia

Novel antidepressant targets brain receptors responsible for learning and memory

Scientists identify novel mechanism by which ketogenic diet could delay effects of aging

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News